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Background: The chemokine fractalkine (CX3CL1, FKN) is involved in neural-microglial interactions and is regarded
as neuroprotective according to several in vivo studies of inflammatory and degenerative states of the brain.
Recently, an association with outcome in human ischemic stroke has been proposed. In this study, we aimed to
investigate the temporal pattern of FKN levels in acute ischemic stroke in relation to stroke severity and outcome.
Methods: FKN levels were measured in plasma specimens of fifty-five patients with acute ischemic stroke. Blood
was available for time points 6 hours (h), 12 h, 3 days (d), 7 d and 90 d after stroke onset. Clinical outcome was
evaluated using the modified Rankin Scale (mRS) at 7 d and 90 d.
Results: The time course of FKN significantly differs depending on stroke severity, with higher FKN levels linked to
a lower severity. FKN levels in patients with moderate to severe strokes differ significantly from controls. In outcome
analysis, we found an association of dynamics of FKN with clinical outcome. Decrease of FKN is pronounced in
patients with worse outcome. Multivariate analysis including stroke severity and stroke etiology revealed that
deltaFKN between 6 h and 3 d is independently associated with mRS at 90 d. In addition deltaFKN is inversely
correlated with the extent of brain damage, as measured by S100B.
Conclusions: FKN dynamics are independently associated with stroke outcome. Further studies might give insight
on whether FKN is actively involved in the inflammatory cascade after acute ischemic stroke.
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Fractalkine (CX3CL1, FKN) is the only chemokine with
the CX3C motif and was first described in 1997 [1]. It
appears to be unique because it exists in a membrane-
bound, as well as in a soluble, form after being cleaved
mainly through a disintegrin and metalloproteinase
domain-containing protein 10 (ADAM10) [2]. FKN has
chemotactic and adhesive functions for inflammatory
cells. Its corresponding receptor, CX3CR1, is expressed
mainly on monocytes, natural killer cells, T-lymphocytes
and microglia.* Correspondence: Worthmann.Hans@mh-hannover.de
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unless otherwise stated.FKN appears on the surface of endothelial cells and
neurons and has been associated with several, mainly in-
flammatory, pathologies such as rheumatoid diseases [3],
atherosclerosis, and neurodegenerative disorders like Alz-
heimer’s [4] and Parkinson’s disease [5]. In the brain, the
CX3CL1/CX3CR1 axis takes part in neural-microglial sig-
naling [6-8].
Recently, FKN has become notable in stroke research,
primarily in animal models and in in vitro studies. The
distinct roles of FKN and its receptor in cerebral ische-
mia are not yet sufficiently investigated and whether
FKN adopts neuroprotective or neurotoxic functions
remains controversial. Rodents treated with exogenous
FKN after permanent occlusion of the middle cerebral
artery (pMCAO) had smaller infarction sizes and less
neurological deficits [9]. Controversially, geneticallyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ceptible to cerebral ischemia [9-11]. In inflammatory
states of the brain, FKN probably acts via modulatory
effects on microglia [12,13], which exert crucial activ-
ities in the response after ischemia. Thus, the interac-
tions between neurons and microglia, mediated by the
CX3CL1/CX3CR1 pathway could be essential in the
pathology of stroke. In contrast to most other markers
in stroke, FKN might, therefore, be less reactively
driven by post-ischemic inflammation, but could be
taking part in the process itself.
Donohue et al. recently proposed that higher FKN
plasma levels are associated with better 180d-Outcome
of ischemic stroke [14]. Based on these results we aimed
to investigate the temporal pattern of FKN plasma levels
in the hyperacute as well as long-term stage of ischemic




Fifty-five ischemic stroke patients were included into the
current study. The patients derived from a cohort of a
former study on inflammation markers in ischemic stroke
that was successively recruited between January 2007 and
April 2009 at the Department of Neurology at Hannover
Medical School [15]. Patients with malignant tumor, im-
munological disease, cerebral hemorrhage and infections,
as well as those with C-reactive protein (CRP) levels >50
mg/l, were excluded from further analysis.
Blood was drawn at time points: 6 hours (h), 12 h, 24
h, 3 days (d) and 7 d after stroke onset. For 50 patients,
additional samples were available for 90 d after stroke
onset.
In addition, measurements of fractalkine levels were
performed in samples of 32 control subjects with cardio-
vascular risk factors (CVRF) but no history of cardiovas-
cular events in the past 3 months. This was necessary to
exclude a probable influence of CVRF in the comparison
of patients with controls.
All specimens were centrifuged with 3,000 rpm for 10
minutes and then stored at -80°C until measurement.
The study was approved by the ethics committee of
Hannover Medical School. All patients or legal represen-
tatives and volunteers provided written informed con-
sent before inclusion in the study.
Clinical evaluation
For every patient, demographic and clinical data such
as cardiovascular risk factors (hypertension, diabetes
mellitus, nicotine consumption and lipid dysregulation)
or intravenous thrombolytic treatment with reverse
tissue-type plasminogen activator (rtPA) were obtained.
In addition, complete blood counts and creatinine levelswere available for each stroke patient. For stroke severity,
the National Institutes of Health Stroke Scale (NIHSS) has
been obtained on admission. Patients were subdivided into
two groups. According to the median, the cut-off was laid
at NIHSS = 3. The groups were defined as mild (NIHSS ≤3)
and moderate/severe (NIHSS >3) strokes [16]. The clinical
outcome was categorized using the modified Rankin Scale
at 7 d and 90 d after stroke onset. The outcome was de-
fined as favorable (mRS: 0 to 1) or unfavorable (mRS: 2 to
6) [17,18]. The proportional differences of FKN levels
(ΔFKN) were calculated as the difference of the value
at admission (6 h) and a later time point, divided by the
6-h value. Stroke etiology was categorized according to the
results of Doppler ultrasound of the brain-supplying ves-
sels, transthoracic/transesophageal echocardiography, and
imaging studies of the brain (cranial computer tomog-
raphy or magnetic resonance imaging) using the TOAST
Criteria [19].
Laboratory studies
FKN levels were determined in EDTA plasma using
ELISA kits (R&D Systems, Inc., Minneapolis, MN, USA).
The sensitivity of the assay was 0.018 ng/mL. Blood con-
centrations of the markers IL-6, S100B, CRP, MMP-9,
TIMP-1 and MCP-1 had been measured in the course of
previous studies of our group [15] and were available for
controls and all patients at the same time points as men-
tioned above with few exceptions [for distinct patient
numbers see Additional file 1: Table S3-8]. Measure-
ments were made by researchers blinded to the patient’s
characteristics.
Statistical analysis
Statistical analysis was done using IBM SPSS Statistics 20
(SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5
(GraphPad Software, Inc., La Jolla, CA, USA). Gaussian dis-
tribution was tested using the Kolmogorov-Smirnov test.
Comparisons between groups were done using Student’s
t-test for normally distributed data or Mann-Whitney
U-test for non-normally distributed data and Chi-square
test for categorical data. Correlations were calculated with
bivariate Pearson correlation or Spearman correlation, as
appropriate. Multivariate logistic regression was performed,
including stroke severity and gender, as those were signifi-
cantly different at baseline, and stroke etiology. This was
done to exclude the probable influence of the underlying
disease. A P value <0.05 was regarded as significant. For




The median age of the study population (n = 55) was 69
years and of the controls (n = 32) 71 years. For further
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Gender differed between patients and controls (P<0.05).
Other baseline characteristics did not differ.
Levels of fractalkine in stroke patients compared to
controls
Comparison of the values in stroke patients with those
in controls with CVRF revealed the following differ-
ences: FKN levels did not differ from those in controls
for the whole group of stroke patients. When patients
with mild (NIHSS ≤3) and moderate/severe strokes
(NIHSS >3) were analyzed separately, significant differ-
ences were observed. At time points 3 d (P = 0.008) and
7 d (P = 0.046), FKN levels of patients with moderate/se-
vere stroke were significantly lower than those in con-
trols and tended to be lower at 90 d (P = 0.082). On the
contrary, levels in patients with mild stroke tended to be
higher than in controls at 6 h (P = 0.055) (Figure 1).
Time course of fractalkine depending on stroke severity
FKN levels differed at time points 3 d (P = 0.014) and 90
d (P = 0.025) and tended to vary at 7 d (P = 0.099) in pa-
tients with mild compared to moderate/severe stroke on
admission (Figure 1). Regarding the temporal profile,
FKN plasma levels decrease after ischemic stroke from
the 6-h value until 7 d for the whole stroke patientTable 1 Baseline characteristics of the study population





Female 25 (45%) 10
Male 30 (55%) 23
Age (Years, Median) (25th to 75th percentiles) 69 (62 to 77 ) 68
Etiology
Large artery atherosclerosis 8 (15%) 3 (
Cardioembolism 14 (25%) 7 (
Small vessel occlusion 13 (24%) 10
Undetermined 20 (36%) 13
Stroke severity
Mild 28 (51%) 23
Moderate/severe 27 (49%) 10
SBP (mmHg, Median) (25th to 75th percentiles) 135 (130 to 143) 13
DBP (mmHg, Median) (25th to 75th percentiles) 80 (70 to 86) 80
Hypertension 34 (62%) 19
Nicotine consumption 10 (18%) 7 (
Dyslipoproteinemia 19 (35%) 12
Diabetes mellitus 6 (11%) 3 (
i.v. rtPA 8 (15%) 3 (
Kruskal-Wallis test or Chi-square compared the groups (favorable, unfavorable strok
i.v. rtPA, intravenous reverse tissue-type plasminogen activator; SBP, systolic bloodgroup (P<0.001). For patients with moderate/severe
stroke, the intragroup comparison showed that levels
significantly decline, even until 90 d after stroke onset.
Conversely, in patients with mild strokes, FKN reaches
initial levels again after a shorter suppression of 3 d
(Figure 1).
Association of dynamics of fractalkine with stroke
outcome
Total levels of FKN were not different between patients
with favorable (mRS: 0 to 1) and unfavorable 7-d or 90-
d outcome (mRS: 2 to 6) at any time point (P>0.05).
Since significant alterations were found between the ini-
tial levels and follow-up time points regarding stroke se-
verity, we compared ΔFKN between patients with
favorable and unfavorable outcome. Patients with favor-
able outcome showed significantly less decrease of FKN
than patients with unfavorable outcome. There were differ-
ences of ΔFKN for the time interval 6 h to 3 d (P = 0.011),
as well as 6 h to 90 d (P = 0.009) regarding the 7-d outcome
(Figure 2). Also, we found differences of ΔFKN between 6 h
and 3 d (P = 0.002) regarding the 90-d outcome (Figure 3).
In a multivariate analysis including stroke severity, gender
and stroke etiology according to TOAST criteria, it was an-
alyzed whether ΔFKN was independently associated with




Control (n = 32) P value
0.014
(30%) 15 (68%) 18 (56%)
(79%) 7 (32%) 14 (44%)
(62 to 74) 76,5 (57,75 to 85) 71 (61,25 to 75,75) 0.277
0.258
9%) 5 (23%) -
21%) 7 (32%) -
(30%) 3 (14%) -
(39%) 7 (32%) -
0.001
(70%) 5 (23%) -
(30%) 17 (77%) -
5 (130 to 142) 135 (129 to 145,25) 130 (120 to 140) 0.453
(70 to 88,5) 80 (70 to 85) 80 (70 to 90) 0.344
(58%) 15 (68%) 24 (75%) 0.325
21%) 3 (14%) 6 (19%) 0.495
(36%) 7 (32%) 17 (53%) 0.224
9%) 3 (14%) 4 (13%) 0.853
9%) 5 (23%) - 0.160
es and controls). P<0.05 is considered significant. DBP, diastolic blood pressure;
pressure,
Figure 1 Differences of fractalkine (FKN) levels at different time
points after stroke onset depending on stroke severity (means ±
SD). Asterisks indicate significant differences between the two
groups mild (NIHSS ≤3) and moderate/severe strokes (NIHSS >3).
Number signs below the error bars indicate significant differences
between moderate/severe stroke patients and controls. Within-
group comparisons of FKN levels between the 6-hour (h) value and
follow-up time points: significant differences were detected for the
group of patients with mild strokes between 6 h and 12 h (P<0.001),
6 h and 24 h (P = 0.003), 6 h and 3 days (d) (P<0.001). For patients
with moderate/severe strokes, significant differences were detected
between 6 h and 24 h (P = 0.006), 6 h and 3 d (P<0.001), 6 h and 7
d (P<0.001) and 6 h and 90 d (P = 0.027).
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and 3 d with 90-d outcome (P = 0.031, OR = 0.011).
Correlation of fractalkine with brain damage and
inflammatory markers and leucocyte counts
In the control group, FKN levels correlated positively with
CRP and TIMP-1 (Table 2). In stroke patients ΔFKN be-
tween 6 h and 3 d inversely correlated with S100B at 24 h
(r = −0.441, P = 0.001) [see Additional file 1: Table S7].Figure 2 Proportional differences of fractalkine levels (ΔFKN) at differ
outcome (means ± SD).There was no correlation between FKN levels or ΔFKN
with inflammatory markers or leucocyte counts in the
stroke patient group considering correction for multiple
comparisons [see Additional file 1: Table S3-S6 and
Additional file 1: Table S8].
Discussion
The main findings of this study are: (i) FKN levels in pa-
tients with moderate to severe ischemic stroke differ
from controls at distinct time points; (ii) after ischemic
stroke, the temporal profile of FKN levels differs in re-
gard to stroke severity; (iii) dynamics of FKN are inde-
pendently associated with neurological outcome; (iv)
dynamics of FKN inversely correlate with the extent of
brain damage as measured by S100B; and (v) the correl-
ation between FKN and CRP and TIMP-1 that is present
in healthy controls is not present in stroke patients, nei-
ther in the acute nor in the prolonged stage.
In this study, we observed an alteration of FKN levels
after stroke compared to controls with CVRF, depending
on stroke severity. Although we provide early levels of
fractalkine, we cannot give any information about FKN
dynamics in the phase before 6 h after stroke. However,
at 3 d, at 7 d, and by tendency, at 90 d in patients with
moderate/severe strokes, FKN levels are reduced com-
pared to controls, while levels in patients with mild
strokes are not. With this study, we are not able to an-
swer whether FKN is released into plasma reactively, or
whether it is itself intervening in the cascade of post-
ischemic inflammation. At 90 days after stroke - a time
point, at which post-stroke inflammation has decreased -
FKN levels still differ between patients with mild and
moderate/severe strokes. This might hint at an individual
potential for regulating FKN. Furthermore, FKN might be
rapidly regulated after the onset of stroke, since it differs
at early time points after stroke depending on stroke
severity.
Donohue et al. described the levels of FKN being linked
to long-term outcome as measured by 180d-mRS [14].ent time points after stroke depending on 7-day (d) stroke
Figure 3 Proportional differences of fractalkine levels (ΔFKN) at different time points after stroke depending on 90-day (d) stroke
outcome (means ± SD).
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stroke evolves rapidly, we aimed to investigate the associ-
ation between early FKN levels and clinical outcome. Re-
garding the absolute levels of FKN, we could not find an
association with outcome but could demonstrate a linkage
only to stroke severity on admission. However, in the
current study we could demonstrate that less decrease of
FKN over time is related to a beneficial stroke outcome.
In concordance to that, less decrease of FKN is also asso-
ciated to smaller infarction sizes, represented by lower
values of the damage marker S100B. This might support
the assumption of an important linkage of FKN with the
pathology of stroke.
Although there is some controversy about its distinct
functions, the chemokine FKN has been regarded to fulfill
a neuroprotective role in several in vitro and in vivo models
of neurodegenerative and neuroinflammatory diseases. One
hypothesis is that the interaction of the neuron-expressed
FKN and its corresponding receptor, CX3CR1, which is
found on microglia, leads to an inhibition of microglial de-
structive inflammation [4,5,20,21]. Treatment of microglia
with FKN in vitro, for example, provokes an inhibition of
cell death mechanisms through Fas ligand-induced cell
death and other pro-apoptotic mechanisms [22]. Further-
more, it has been shown in a cell culture model that sur-
vival of hippocampal neurons can be induced by the
presence of FKN via the protein kinase Akt pathway [23].Table 2 Correlations of fractalkine to brain damage and
inflammation markers within the control cohort
R P
FKN versus CRP 0.562 0.001a
FKN versus MCP-1 0.391 0.027
FKN versus TIMP-1 0.676 <0.001a
FKN versus MMP-9 0.402 0.023
FKN versus IL-6 0.227 0.211
FKN versus S100B -0.105 0.566
aP<0.008: significant after Bonferroni correction.High levels of FKN might also play a role in cell death after
stroke.
The main differences in ΔFKN were observed for the
time interval from 6 h to 3 d. This could be because
FKN may take part in the recruitment of leucocytes. In a
murine stroke model, it has been shown that the influx
of immune cells (for example, macrophages, lympho-
cytes and neutrophils) peaks at 1 to 3 d after ischemia
[24]. Additionally, the infiltration of macrophages in the
post-ischemic brain significantly increases between day 1
and day 4 after an experimental stroke [25]. Especially
the nonclassical subset of monocytes, which expresses
high levels of CX3CR1, could be of particular import-
ance in the FKN-dependent recruitment of cells. Urra et
al. reported a significant proportional decrease of non-
classical monocytes at 2 d after stroke onset. They also
described an inverse association of these cells with in-
farct size and outcome [26]. This might be in line with
our findings about the inverse association of ΔFKN with
infarct size and outcome. Although it has been shown
that monocyte subsets are involved in the post-ischemic
inflammatory processes [27], detailed investigations of
monocyte recruitment in connection with FKN and
other chemokines to the brain are lacking. In a murine
model of myocardial infarction, Ly-6Clow monocytes,
which are comparable to the human nonclassical subset,
dominate a second phase of inflammatory response, which
starts at some days after ischemia and have been regarded
as reparative [28] (for review see: [29]). Recruitment of
Ly-6Clow monocytes to the post-ischemic myocardium is
executed via FKN. Also after stroke, the migration of
potentially protective nonclassical monocytes might be
dependent on FKN. Possibly, a neuroprotective charac-
teristic of FKN could, therefore, also be explained by a
chemotactic impact on nonclassical monocytes. Mea-
surements of the expression of CX3CR1 on circulating
leukocytes would be helpful in future studies to ad-
dress this point and to investigate the association of re-
ceptor expression and plasma FKN dynamics. While
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tive effect of FKN, its impact in patients is uncertain.
So far, it even remains unclear if concentrations of
FKN in plasma are accurately reflecting its actions in
the central nervous system.
FKN is also present on the surface of endothelial cells
and contributes to chemotaxis and invasion of inflam-
matory cells, such as, for example, monocytes [30,31].
The CX3CL1/CX3CR1 axis is therefore suspected to
carry out pro-atherogenetic functions, as it might con-
tribute to formation of atherosclerotic lesions [32-35]. In
our control collective, which contains individuals with
cardiovascular risk factors, CRP levels are strongly corre-
lated to FKN, implying that there might be a linkage to
cardiovascular risk in humans. Recently, FKN was sug-
gested to be an independent predictor of cardiovascular
mortality in a heart failure patient cohort [36]. As FKN
levels might be distorted by atherosclerotic diseases we
also included the etiology of stroke in our multivariate
model. But, ΔFKN was independently associated with
clinical stroke outcome.
While FKN levels correlate significantly with CRP and
TIMP-1 in healthy controls, there is no association in
stroke patients. The fact that the associations are not re-
stored until 90 d after stroke may underline the long-
term impact of the acute event. The finding that there
are no correlations to other markers of inflammation in
stroke patients is in accordance to the different specific
dynamics of FKN in stroke.
Although we provide evidence of an independent associ-
ation of FKN dynamics with stroke outcome, and therefore
present FKN as a putative future biomarker in stroke, the
interpretation of the data must be done cautiously. Consid-
ering the multifactorial pathology of ischemic stroke, the
patient cohort is relatively small. For that reason, we also
could not evaluate a probable effect of any treatment, such
as, for example, thrombolysis. Furthermore, despite strict
exclusion criteria, an overlap of pre-ischemic inflammation
processes that might distort the results cannot be ruled out
completely. Due to strict exclusion criteria concerning in-
fectious diseases, we could include relatively fewer patients
with severe strokes. Finally, as this is a retrospective study,
measurements of CX3CR1 expression on vital leucocytes
could not be done.
Conclusions
In this study, we investigated, for the first time, the behav-
ior of FKN levels in the hyperacute stage after ischemic
stroke in humans. Early FKN dynamics are independently
related to stroke outcome. Supported by former animal
and in vitro studies, FKN might be involved in the inflam-
matory cascade after acute ischemic stroke and could
serve as a new biomarker, especially concerning its rapid
regulation. However, due to the nature of the study weonly can provide associations of FKN with stroke but no
causality. The exact mechanisms need to be illuminated in
future studies.
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